Literature DB >> 25819500

Elevated Hippocampal Cholinergic Neurostimulating Peptide precursor protein (HCNP-pp) mRNA in the amygdala in major depression.

Sabrina Bassi1, Marianne L Seney1, Pablo Argibay2, Etienne Sibille3.   

Abstract

The amygdala is innervated by the cholinergic system and is involved in major depressive disorder (MDD). Evidence suggests a hyper-activate cholinergic system in MDD. Hippocampal Cholinergic Neurostimulating Peptide (HCNP) regulates acetylcholine synthesis. The aim of the present work was to investigate expression levels of HCNP-precursor protein (HCNP-pp) mRNA and other cholinergic-related genes in the postmortem amygdala of MDD patients and matched controls (females: N = 16 pairs; males: N = 12 pairs), and in the mouse unpredictable chronic mild stress (UCMS) model that induced elevated anxiety-/depressive-like behaviors (females: N = 6 pairs; males: N = 6 pairs). Results indicate an up-regulation of HCNP-pp mRNA in the amygdala of women with MDD (p < 0.0001), but not males, and of UCMS-exposed mice (males and females; p = 0.037). HCNP-pp protein levels were investigated in the human female cohort, but no difference was found. There were no differences in gene expression of acetylcholinesterase (AChE), muscarinic (mAChRs) or nicotinic receptors (nAChRs) between MDD subjects and controls or UCMS and control mice, except for an up-regulation of AChE in UCMS-exposed mice (males and females; p = 0.044). Exploratory analyses revealed a baseline expression difference of cholinergic signaling-related genes between women and men (p < 0.0001). In conclusion, elevated amygdala HCNP-pp expression may contribute to mechanisms of MDD in women, potentially independently from regulating the cholinergic system. The differential expression of genes between women and men could also contribute to the increased vulnerability of females to develop MDD.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acetylcholine; Amygdala; Cholinergic system; Depression; Hippocampal Cholinergic Neurostimulating Peptide; Postmortem; mRNA gene expression

Mesh:

Substances:

Year:  2015        PMID: 25819500      PMCID: PMC4387107          DOI: 10.1016/j.jpsychires.2015.02.006

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  58 in total

1.  Projections from the amygdaloid complex to the magnocellular cholinergic basal forebrain in rat.

Authors:  E Jolkkonen; R Miettinen; M Pikkarainen; A Pitkänen
Journal:  Neuroscience       Date:  2002       Impact factor: 3.590

2.  NMDA receptor activation enhances the release of a cholinergic differentiation peptide (HCNP) from hippocampal neurons in vitro.

Authors:  K Ojika; Y Tsugu; S Mitake; Y Otsuka; E Katada
Journal:  Brain Res Dev Brain Res       Date:  1998-03-12

3.  Mechanism of expression of the rat HCNP precursor protein gene.

Authors:  N Tohdoh; S Tojo; M Kimura; T Ishii; K Ojika
Journal:  Brain Res Mol Brain Res       Date:  1997-04

4.  Acetylcholine and depression.

Authors:  D S Janowsky; M K el-Yousef; J M Davis
Journal:  Psychosom Med       Date:  1974 May-Jun       Impact factor: 4.312

5.  Scopolamine produces larger antidepressant and antianxiety effects in women than in men.

Authors:  Maura L Furey; Ashish Khanna; Elana M Hoffman; Wayne C Drevets
Journal:  Neuropsychopharmacology       Date:  2010-08-25       Impact factor: 7.853

6.  Purification and structural analysis of hippocampal cholinergic neurostimulating peptide.

Authors:  K Ojika; S Kojima; Y Ueki; N Fukushima; K Hayashi; M Yamamoto
Journal:  Brain Res       Date:  1992-02-14       Impact factor: 3.252

Review 7.  Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis.

Authors:  Yann S Mineur; Marina R Picciotto
Journal:  Trends Pharmacol Sci       Date:  2010-10-19       Impact factor: 14.819

8.  Limbic-frontal circuitry in major depression: a path modeling metanalysis.

Authors:  D A Seminowicz; H S Mayberg; A R McIntosh; K Goldapple; S Kennedy; Z Segal; S Rafi-Tari
Journal:  Neuroimage       Date:  2004-05       Impact factor: 6.556

9.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang
Journal:  JAMA       Date:  2003-06-18       Impact factor: 56.272

10.  Decreased hippocampal cholinergic neurostimulating peptide precursor protein associated with stress exposure in rat brain by proteomic analysis.

Authors:  Hong Gi Kim; Kil Lyong Kim
Journal:  J Neurosci Res       Date:  2007-10       Impact factor: 4.164

View more
  4 in total

1.  Gene expression in the amygdala and hippocampus of cyclic and acyclic gilts.

Authors:  Hiruni R Wijesena; Dan J Nonneman; Brittney N Keel; Clay A Lents
Journal:  J Anim Sci       Date:  2022-01-01       Impact factor: 3.159

Review 2.  Sex-Specific Brain Transcriptional Signatures in Human MDD and Their Correlates in Mouse Models of Depression.

Authors:  Maureen Touchant; Benoit Labonté
Journal:  Front Behav Neurosci       Date:  2022-05-03       Impact factor: 3.617

3.  Opposite Molecular Signatures of Depression in Men and Women.

Authors:  Marianne L Seney; Zhiguang Huo; Kelly Cahill; Leon French; Rachel Puralewski; Joyce Zhang; Ryan W Logan; George Tseng; David A Lewis; Etienne Sibille
Journal:  Biol Psychiatry       Date:  2018-02-19       Impact factor: 13.382

4.  Sex-specific transcriptional signatures in human depression.

Authors:  Benoit Labonté; Olivia Engmann; Immanuel Purushothaman; Caroline Menard; Junshi Wang; Chunfeng Tan; Joseph R Scarpa; Gregory Moy; Yong-Hwee E Loh; Michael Cahill; Zachary S Lorsch; Peter J Hamilton; Erin S Calipari; Georgia E Hodes; Orna Issler; Hope Kronman; Madeline Pfau; Aleksandar L J Obradovic; Yan Dong; Rachael L Neve; Scott Russo; Andrew Kazarskis; Carol Tamminga; Naguib Mechawar; Gustavo Turecki; Bin Zhang; Li Shen; Eric J Nestler
Journal:  Nat Med       Date:  2017-08-21       Impact factor: 53.440

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.